Methodological problems in evaluating duration of response to therapy in cancer clinical trials

Oncology Research and Treatment

Volumn 20, Issue 5, 1997, Pages 393-399

  Schroder T ^a   Schumacher, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Duration of response; Overall survival; Probability of being in response function; Response rate

Indexed keywords

BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; COMPUTER SIMULATION; METASTASIS; PROBABILITY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0030710088     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218990     Document Type: Article

References (20)

1. Anderson JR, Cain KC, Gelber RD, Gelman RS: Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials, Cancer Treat Rep 1985;69:1139 -1144.
2. Mantel N, Byar DP: Evaluation of response-time data involving transient states: An illustration using heart-transplant data, J Am Stat Assoc 1974:69: 81-86.
3. Mantel N: An uncontrolled clinical trial - treatment response or spontaneous improvement? Control Clin Trials 1982:3:369-370.
4. Oye RK, Shapiro ME: Reporting results from chemotherapy trials, JAMA 1984:252:2722-2725.
5. Simon R, Makuch RW: A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus nonresponder bias, Stat Med 1984:3:35-44.
6. Weiss GB, Bunco II, III, Hokanson JA: Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trials, Control Clin Trials 1983:4:43-52.
7. Buysc M, Piedbois P: On the relationship between response to treatment and survival time, Slat Med 1996:15:2797-2812.
8. Cox DR: Regression models and lifo-tables (with discussion), J Royal Stat Soc B 1972:34:187-220.
9. Wahrcndorf J: The joint analysis of survival times and response rates in clinical trials on the treatment of cancer, Methods Inf Med 1980:19:112-114.
10. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial, J Clin Oncol 1995:13:2483-2489.
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations, J Am Stat Assoc 1958:53:457-481.
12. Andersen P, Borgan O, Jill RD, Keiding N: Statistical Models Based on Counting Processes, Heidelberg, Springer Verlag, 1993.
13. Tenikin NR: An analysis for transient states with application to tumor shrinkage, Biometrics 1978:34:571-580.
14. Edler L, Flechtner H: Remission in Phase-Il- und Phase-Ill-Studien: Kriterien und Voraussetzungen, Onkologie 1987:10:330-339.
15. Green S, Weis GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria, Invest New Drugs 1992; 10:239-252.
16. I Iavward JL, Meakin J W, Stewart IIJ: Assessment of response and recurrence in breast cancer, Semin Oncol 1978:5:445-449.
17. Grüger J, Kay R, Schumacher M: The validity of inferences based on incomplete observations in disease state models, Biometrics 1991:47:595-605.
18. Rücker G, Messerer D: Remission duration: An example of interval-censored observations, Stat Med 1988:7:1139-1145.
19. Warr D, McKinney S, Tannock I: Influence of measurement on assessment of response to anticancer chemotherapy: Proposals for new criteria of tumor response, J Clin Oncol 1984:2:1040-1046.
20. Morgan TM: Analysis of duration of response, A problem of oncology trials, Control Clin Trials 1988:9:11-18